Retrospective Analysis of 68Ga-PSMA-PET in Patients With Prostate Cancer: Experience From Brazil

Inclusion Criteria

• •1. Age of at least 18 years at study entry;
• •2. Histologically confirmed adenocarcinoma of the prostate;
• •3. 68Ga-PSMA-PET exam performed between October 2015 and January 2021;
• •4. 68Ga-PSMA-PET performed in one of the following situations:
• •* localized disease at diagnosis in patients with no detection of extra-prostatic disease in traditional imaging such as CT scan, MRI and bone scan;
• •* biochemical recurrence (according to PCWG3 or defined by the investigator) in patients with no detection of prostatic or extra-prostatic disease in traditional imaging such as CT scan, MRI and bone scan;
• •5. Traditional imaging (pelvic and abdominal CT or MRI and bone scan) with negative results (no extra-prostatic disease, for localized and biochemical recurrence disease; no prostatic for biochemical recurrence disease) performed within 8 weeks before 68Ga-PSMA-PET;
• •6. Site and investigator ability to collect adequate patient characteristics, treatment and outcome data from medical records.